IGI Laboratories, Inc. Announces Michael B. Hemric Appointed to Its Board of Directors

BUENA, N.J.--(Business Wire)--
IGI Laboratories, Inc.(NYSE AMEX:IG), a premier provider of topical formulation
development, analytical, manufacturing and packaging services today announced
that Michael B. Hemric has been appointed to the company's board of directors.
Mr. Hemric will take the place of Mr. Steven J. Morris who resigned from the
company`s board of directors effective July 1, 2009.

"We are very pleased to have Mike join our board of directors. Mike is a
successful executive with extensive knowledge of the generic and branded
pharmaceutical market. As we advance our over the counter and prescription
product development portfolio and broaden our presence within the specialty
pharmaceutical sector, his considerable strategic planning and commercial
development experience will be invaluable to IGI. In addition, the Board
sincerely thanks Steven for his support and strong contribution to IGI over his
tenure as a board member," said Ms. Joyce Erony, Chairperson of IGI
Laboratories, Inc.

Mr. Hemric, has over 30 years of experience in the consumer healthcare industry.
From February 1981 until his retirement in February 2008, he held various senior
management positions at Alcon Laboratories including General Manager of Alcon`s
Consumer Product and Pharmaceutical divisions and most recently as President of
its Far East division. Mr. Hemric received a B.A. from Wake Forest University
and is a graduate of the Harvard Program for Management Development.

About IGI Laboratories, Inc.

IGI Laboratories, Inc. engages in the development, manufacturing, filling, and
packaging of topical, semi solid, and liquid products for pharmaceutical and
cosmeceutical companies. The Company offers the patented Novasome encapsulation
technology which contributes value-added qualities to pharmaceutical and
cosmeceutical products, providing improved dermal absorption and sustained
release of the active molecule.

IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995. This press release includes certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements include, but are
not limited to, plans, objectives, expectations and intentions, and other
statements contained in this press release that are not historical facts and
statements identified by words such as "will," "possible," "one time," "provides
an opportunity," "continue" or words of similar meaning. These statements are
based on our current beliefs or expectations and are inherently subject to
various risks and uncertainties, including those set forth under the caption
"Risk Factors" in IGI Laboratories, Inc.`s most recent Annual Report on Form
10-K and Quarterly Report on Form 10-Q as filed with the Securities and Exchange
Commission. Actual results may differ materially from these expectations due to
changes in global political, economic, business, competitive, market and
regulatory factors or IGI Laboratories, Inc.`s ability to implement business
strategies. IGI Laboratories, Inc. does not undertake any obligation to update
any forward-looking statements contained in this document as a result of new
information, future events or otherwise.

IGI Laboratories, Inc.
Philip S. Forte, 856-697-1441 ext. 363
www.askigi.com

Copyright Business Wire 2009